JUBLPHARMA vs PPLPHARMA: Stock Comparison

Jubilant Pharmova Limited vs Piramal Pharma Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Jubilant Pharmova Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Piramal Pharma Limited shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Jubilant Pharmova Limited and Piramal Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, JUBLPHARMA is more favourable on 11 of 13 scored metrics and PPLPHARMA on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹23,554 Cr vs ₹15,512 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-75.43x vs 39.79x
P/B Ratio
JUBLPHARMA has a lower P/B
2.24x vs 3.01x
EPS
JUBLPHARMA has higher earnings per share
₹25.05 vs ₹-2.45
Dividend Yield
JUBLPHARMA has a higher dividend yield
0.52% vs 0.08%
Revenue Growth (TTM YoY)
JUBLPHARMA has faster revenue growth
18.7% vs -0.1%
EPS Growth (TTM YoY)
PPLPHARMA has faster EPS growth
0% vs -22.4%
Qtr Sales Growth
JUBLPHARMA has stronger quarterly sales growth
18.7% vs -0.08%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricJUBLPHARMAPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricJUBLPHARMAPPLPHARMA
Live Price₹996₹177.1
Day Change-1.17%-4.17%
Volume89,29679 L
52-Week High₹1,248₹212.39
52-Week Low₹786.05₹132.3
Distance from 52W High-20.19%-16.62%

Valuation

MetricJUBLPHARMAPPLPHARMA
Market Cap₹15,512 Cr₹23,554 Cr
P/E Ratio39.79x-75.43x
P/B Ratio2.24x3.01x
EPS₹25.05₹-2.45
Book Value₹448.5₹64.78
Dividend Yield0.52%0.08%

Growth

MetricJUBLPHARMAPPLPHARMA
Revenue Growth (TTM YoY)18.7%-0.1%
EPS Growth (TTM YoY)-22.4%0%
Qtr Sales Growth18.7%-0.08%
Qtr Profit Growth-17.4%-25%

Profitability & Leverage

MetricJUBLPHARMAPPLPHARMA
ROE6.55%-3.83%
ROCE8.99%2.52%
Net Margin5.28%-3.68%
Operating Margin15.2%10.4%
Debt to Equity0.51x0.7x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricJUBLPHARMAPPLPHARMA
Promoter Holding44.39%34.86%
FII Holding15.9% 0.06 pp30.18% 0.52 pp
DII Holding11.62% 0.4 pp15.61% 0.08 pp
Public Holding24.24% 0.33 pp19.01% 0.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Jubilant Pharmova Limited and Piramal Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.